BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah TU, Semelka RC, Pamuklar E, Firat Z, Gerber RD, Shrestha R, Russo MW. The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroenterol 2006;101:533-40. [PMID: 16542290 DOI: 10.1111/j.1572-0241.2006.00450.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Russo MW. Current concepts in the evaluation of patients for liver transplantation. Expert Review of Gastroenterology & Hepatology 2014;1:307-20. [DOI: 10.1586/17474124.1.2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lee JM, Choi BI. Hepatocellular nodules in liver cirrhosis: MR evaluation. Abdom Imaging 2011;36:282-9. [DOI: 10.1007/s00261-011-9692-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
3 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wu S, Tu R, Liu G, Shi Y. Dynamic changes in ultrasound characteristics of nodules in cirrhotic liver and their implications in surveillance for malignancy. J Med Ultrason (2001) 2014;41:165-71. [PMID: 27277769 DOI: 10.1007/s10396-013-0494-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
6 Choi D, Mitchell DG, Verma SK, Bergin D, Navarro VJ, Malliah AB, McGowan C, Hann HW, Herrine SK. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology 2007;244:776-83. [PMID: 17690322 DOI: 10.1148/radiol.2443061355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
7 Jha RC, Zanello PA, Nguyen XM, Pehlivanova M, Johnson LB, Fishbein T, Shetty K. Small hepatocellular carcinoma: MRI findings for predicting tumor growth rates. Acad Radiol. 2014;21:1455-1464. [PMID: 25300723 DOI: 10.1016/j.acra.2014.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
8 Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Review of Gastroenterology & Hepatology 2014;2:497-508. [DOI: 10.1586/17474124.2.4.497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
9 Klysik M, Garg S, Pokharel S, Meier J, Patel N, Garg K. Challenges of imaging for cancer in patients with diabetes and obesity. Diabetes Technol Ther 2014;16:266-74. [PMID: 24568627 DOI: 10.1089/dia.2014.0026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
10 Ramalho M, Herédia V, Tsurusaki M, Altun E, Semelka RC. Quantitative and qualitative comparison of 1.5 and 3.0 Tesla MRI in patients with chronic liver diseases. J Magn Reson Imaging. 2009;29:869-879. [PMID: 19306415 DOI: 10.1002/jmri.21719] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
11 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
13 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Kim KW, Choi JI. Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1665. [PMID: 34574006 DOI: 10.3390/diagnostics11091665] [Reference Citation Analysis]
14 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kierans AS, Leonardou P, Hayashi P, Brubaker LM, Elazzazi M, Shaikh F, Semelka RC. MRI findings of rapidly progressive hepatocellular carcinoma. Magn Reson Imaging. 2010;28:790-796. [PMID: 20427139 DOI: 10.1016/j.mri.2010.03.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
16 Ganne-carrié N, Piscaglia F. Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk? Journal of Hepatology 2020;72:607-9. [DOI: 10.1016/j.jhep.2020.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 233] [Article Influence: 19.6] [Reference Citation Analysis]
18 Lauenstein TC, Salman K, Morreira R, Heffron T, Spivey JR, Martinez E, Sharma P, Martin DR. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol. 2007;189:663-670. [PMID: 17715115 DOI: 10.2214/AJR.07.2171] [Cited by in Crossref: 39] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
19 Zapparoli M, Semelka RC, Altun E, Tsurusaki M, Pamuklar E, Dale BM, Gasparetto EL, Elias J. 3.0-T MRI evaluation of patients with chronic liver diseases: initial observations. Magn Reson Imaging. 2008;26:650-660. [PMID: 18440749 DOI: 10.1016/j.mri.2008.01.037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
20 Guiu B, Loffroy R, Ben Salem D, Lepage C, Guiu S, Aho S, Jouve JL, Krausé D, Cercueil JP. Combined SPIO-gadolinium magnetic resonance imaging in cirrhotic patients: negative predictive value and role in screening for hepatocellular carcinoma. Abdom Imaging 2008;33:520-8. [PMID: 17912584 DOI: 10.1007/s00261-007-9327-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]